NanoPass Technologies is a commercial stage pioneer in the development of virtually pain-free intradermal delivery solutions for vaccines and drugs. Supported by extensive clinical data and regulatory approvals in leading markets, NanoPass is expanding its global commercial availability and partnership with pharma companies and distributors aiming to provide better patient care worldwide. NanoPass is backed by strategic partners and VCs and is ISO13485 certified. NanoPass’ flagship product, the 0.6mm MicronJetTM, is the smallest delivery device in healthcare to receive FDA clearance as an intradermal delivery device for substances approved for delivery into the skin.